The DOI matches its Crossref record; 109 of the 110 references it cites were found in a registry or an index.
CAR-T cell therapy: current limitations and potential strategies
Open accessAbstract
Chimeric antigen receptor (CAR)-T cell therapy is a revolutionary new pillar in cancer treatment. Although treatment with CAR-T cells has produced remarkable clinical responses with certain subsets of B cell leukemia or lymphoma, many challenges limit the therapeutic efficacy of CAR-T cells in solid tumors and hematological malignancies. Barriers to effective CAR-T cell therapy include severe life-threatening toxicities, modest anti-tumor activity, antigen escape, restricted trafficking, and limited tumor infiltration. In addition, the host and tumor microenvironment interactions with CAR-T cells critically alter CAR-T cell function. Furthermore, a complex workforce is required to develop and implement these treatments. In order to overcome these significant challenges, innovative strategies and approaches to engineer more powerful CAR-T cells with improved anti-tumor activity and decreased toxicity are necessary. In this review, we discuss recent innovations in CAR-T cell engineering to improve clinical efficacy in both hematological malignancy and solid tumors and strategies to overcome limitations of CAR-T cell therapy in both hematological malignancy and solid tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Despite their general tolerability, immune checkpoint inhibitors (ICIs) may induce cytokine storms in patients, and T cell-engaging bispecific antibodies and TCR/CAR-T engineered T cells, contingent on the target, could result in significant off-target tissue destruction, leading to associated morbidity and mortality (Sterner and Sterner, 2021; Johnson et al., 2022).”
From Microphysiological systems as models for immunologically ‘cold’ tumors (2024) · cites this paper as Sterner and Sterner, 2021
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“To address this, various immunotherapeutic strategies have emerged, including adoptive cell transfer, primarily utilizing genetically modified T cells expressing chimeric antigen receptors (CAR T-cells) to recognize and eliminate cancer cells directly (Sterner and Sterner, 2021). Adjuvant therapies, such as dendritic cell, mRNA, and peptide-based vaccinations, aim to boost the patient’s anticancer”
From Microphysiological systems as models for immunologically ‘cold’ tumors (2024) · cites this paper as Sterner and Sterner, 2021
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Despite their general tolerability, immune checkpoint inhibitors (ICIs) may induce cytokine storms in patients, and T cell-engaging bispecific antibodies and TCR/CAR-T engineered T cells, contingent on the target, could result in significant off-target tissue destruction, leading to associated morbidity and mortality (Sterner and Sterner, 2021; Johnson et al., 2022).”
From Microphysiological systems as models for immunologically ‘cold’ tumors (2024) · cites this paper as Sterner and Sterner, 2021
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Microenvironmental regulation of tumor progression and metastasis
Quail, D. F., & Joyce, J. A. (2013) · Nature Medicine · doi:10.1038/nm.3394 · Cited by 7,994
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707447 · Cited by 6,030
Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735
Lee, D. W., Santomasso, B. D., Locke, F. L., Ghobadi, A., Turtle, C. J., Brudno, J. N., Maus, M. V., Park, J. H., Mead, E., Pavletic, S., et al. (2019) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2018.12.758 · Cited by 3,675
Car t cell immunotherapy for human cancer
June, C. H., O’Connor, R. S., Kawalekar, O. U., Ghassemi, S., & Milone, M. C. (2018) · Science · doi:10.1126/science.aar6711 · Cited by 3,207
Current concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
Park, J. H., Rivière, I., Gonen, M., Wang, X., Sénéchal, B., Curran, K. J., Sauter, C., Wang, Y., Santomasso, B., Mead, E., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709919 · Cited by 2,688
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Davila, M. L., Rivière, I., Wang, X., Bartido, S. M., Park, J. H., Curran, K. J., Chung, S. S., Stefanski, J., Bórquez-Ojeda, O., Olszewska, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008226 · Cited by 2,514
Chimeric antigen receptor T-cell therapy—assessment and management of toxicities
Neelapu, S. S., Tummala, S., Kebriaei, P., Wierda, W., Gutierrez, C., Locke, F. L., Komanduri, K. V., Lin, Y., Jain, N., Daver, N., et al. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.148 · Cited by 2,438
Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
Schuster, S. J., Svoboda, J., Chong, E. A., Nasta, S. D., Mato, A. R., Anak, Ö., Brogdon, J. L., Pruteanu-Malinici, I., Bhoj, V. G., Landsburg, D. J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708566 · Cited by 1,891
Research works printed but not linked: 1
- Peter P. Lee (eds.) Tumor Microenvironment (Springer) https://www.springer.com/gp/book/9783030388614
Cited by
Sorted by citations
Items 801–900 of 1,002
AI in cellular engineering and reprogramming
Capponi, S., & Wang, S. (2024) · Biophysical Journal · doi:10.1016/j.bpj.2024.04.001 · Cited by 18
Gene and cell therapy for age-related macular degeneration: A review
Trincão-Marques, J., Ayton, L. N., Hickey, D. G., Marques‐Neves, C., Guymer, R. H., Edwards, T. L., & Sousa, D. C. (2024) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2024.05.002 · Cited by 19
Xu, T., Tian, T., Wang, C., Chen, X., Zuo, X., Zhou, H., Bai, J., Zhao, C., Fu, S., Sun, C., et al. (2024) · Genome Medicine · doi:10.1186/s13073-024-01405-5 · Cited by 18
Setting “cold” tumors on fire: Cancer therapy with live tumor-targeting bacteria
Manole, S., Nguyen, D.-H., Min, J.-J., Zhou, S., & Forbes, N. (2024) · Med · doi:10.1016/j.medj.2024.11.002 · Cited by 17
He, W., Lv, W., Liu, L., Gong, Y., Song, K., Xu, J., Zhao, W., Li, S., Min, Z., Chen, Q., et al. (2024) · ACS Nano · doi:10.1021/acsnano.4c13470 · Cited by 16
Nanocarriers in glioblastoma treatment: a neuroimmunological perspective
Firuzpour, F., Saleki, K., Aram, C., & Rezaei, N. (2024) · Reviews in the Neurosciences · doi:10.1515/revneuro-2024-0097 · Cited by 16
Zhang, H., Dai, J., Mu, Q., Zhao, X., Lin, Z., Wang, K., Wang, M., & Sun, D. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1491872 · Cited by 16
Advancing Allogeneic NK Cell Immunotherapy through Microfluidic Gene Delivery
Kim, H., Lee, M. K., Han, B., Kim, J.-H., Cho, D., Doh, J., & Chung, A. J. (2025) · Advanced Science · doi:10.1002/advs.202412544 · Cited by 16
Cell-based immunotherapies for solid tumors: advances, challenges, and future directions
Zhao, T., You, J., Wang, C., Li, B., Liu, Y., Shao, M., Zhao, W., & Zhou, C. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1551583 · Cited by 15
Advances in Immunotherapies for Gliomas
Zhang, M., Choi, J. H., & Lim, M. K. (2022) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-022-01176-9 · Cited by 16
Rijavec, E., Biello, F., Barletta, G., Dellepiane, C., & Genova, C. (2022) · Molecular and Clinical Oncology · doi:10.3892/mco.2022.2522 · Cited by 16
Immunotherapy for Pediatric Acute Lymphoblastic Leukemia: Recent Advances and Future Perspectives
Lv, M., Liu, Y., Liu, W., Xing, Y., & Zhang, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.921894 · Cited by 18
Engineered microneedle systems for topical cancer therapy
Jiang, X., Xia, W., Pan, J., Yang, W., Zhang, S., Li, C., Zan, T., Lai, Y., Xu, Z., & Yu, H. (2023) · Applied Materials Today · doi:10.1016/j.apmt.2023.101774 · Cited by 16
CAR T treatment beyond cancer: Hope for immunomodulatory therapy of non-cancerous diseases
Yang, Z., Liu, Y., & Hai, Z. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122556 · Cited by 16
Enhancing cell‐based therapies with synthetic gene circuits responsive to molecular stimuli
Galvan, S., Teixeira, A. P., & Fussenegger, M. (2024) · Biotechnology and Bioengineering · doi:10.1002/bit.28770 · Cited by 16
Kametani, Y., Ito, R., Manabe, Y., Kulski, J. K., Seki, T., Ishimoto, H., & Shiina, T. (2024) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2024.1447315 · Cited by 15
The Utilization of PRAME in the Diagnosis, Prognosis, and Treatment of Melanoma
Blount, S. L., Liu, X., & McBride, J. D. (2024) · Cells · doi:10.3390/cells13201740 · Cited by 15
Cao, X., Wan, S., Wu, B., Liu, Z., Xu, L., Ding, Y. J., & Huang, H. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c01277 · Cited by 17
Pancreatic cancer: failures and hopes—a review of new promising treatment approaches
Cereda, V., & D'Andrea, M. R. (2025) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2025.1002299 · Cited by 16
In vivo production of CAR T cell: Opportunities and challenges
Song, Z., Zhou, Y., Wang, B., Geng, Y., Tang, G., Wang, Y., & Yang, J. (2025) · Genes & Diseases · doi:10.1016/j.gendis.2025.101612 · Cited by 17
The Impact of T-cell Exhaustion Dynamics on Tumour–Immune Interactions and Tumour Growth
Lai, N., Farman, A., & Byrne, H. M. (2025) · Bulletin of Mathematical Biology · doi:10.1007/s11538-025-01433-1 · Cited by 19
Dai, Z., Zhu, Z., Li, Z., Tian, L., Teng, K., Chen, H., Wang, L.-S., Zhang, J., Melstrom, L. G., Caligiuri, M. A., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci179014 · Cited by 15
Advances in mRNA vaccine therapy for breast cancer research
Li, J., Jiang, R., Wang, J., & Wang, X. (2025) · Discover Oncology · doi:10.1007/s12672-025-02542-y · Cited by 16
Hushmandi, K., Fooladi, A. A. I., Reiter, R. J., Farahani, N., Liang, L., Aref, A. R., Nabavi, N., Alimohammadi, M., Liu, L., & Sethi, G. (2025) · Experimental Hematology and Oncology · doi:10.1186/s40164-025-00662-3 · Cited by 16
CAR T-cells meet autoimmune neurological diseases: a new dawn for therapy
Chinas, N. A., & Alexopoulos, H. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1604174 · Cited by 17
Fang, W. J., Lu, Z., Ge, J., Zhang, S., Zheng, R., Yin, W., Hao, R., Sun, M., & Luo, T. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.08.014 · Cited by 15
CAR-T cells immunotherapy in the treatment of glioblastoma
Królikowska, A., & Tarnowski, M. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-04222-w · Cited by 16
Progress in the development of cytokine armoured CAR T cells
Prasad, K., Cross, R. S., & Jenkins, M. R. (2026) · Nature reviews. Immunology · doi:10.1038/s41577-026-01280-8 · Cited by 18
Facing CAR T Cell Challenges on the Deadliest Paediatric Brain Tumours
Ferreras, C., Fernández, L., Villa, L. C., Ibáñez-Navarro, M., Martín-Cortázar, C., Esteban‐Rodríguez, I., Saceda-Gutierrez, J. M., & Pérez‐Martínez, A. (2021) · Cells · doi:10.3390/cells10112940 · Cited by 15
Protection is not always a good thing: The immune system’s impact on gene therapy
de Freitas, M. V., Frâncio, L., Haleva, L., & Matte, Ú. D. S. (2022) · Genetics and Molecular Biology · doi:10.1590/1678-4685-gmb-2022-0046 · Cited by 18
Sjöholm, T., Korenyushkin, A., Gammelgård, G., Sarén, T., Lövgren, T., Loskog, A., Essand, M., Kullberg, J., Enblad, G., & Ahlström, H. K. (2022) · Cancer Imaging · doi:10.1186/s40644-022-00513-y · Cited by 15
Sun, S., Huang, C., Lü, M., Xu, H., Yuan, Y., Zhao, W., Hu, X., Wang, B., Zhang, W., Gao, X., et al. (2023) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0531 · Cited by 16
Self-assembled nanoparticles: A new platform for revolutionizing therapeutic cancer vaccines
Shi, T., Sun, M., Lu, C., & Meng, F. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1125253 · Cited by 16
Practical issues in CAR T-cell therapy
Byun, J. M. (2023) · Blood Research · doi:10.5045/br.2023.2023015 · Cited by 15
Gallic acid enhances anti-lymphoma function of anti-CD19 CAR-T cells in vitro and in vivo
Luo, Z., Shi, J., Jiang, Q., Yu, G., Li, X., Yu, Z., Wang, J., & Shi, Y. (2023) · Molecular Biomedicine · doi:10.1186/s43556-023-00122-6 · Cited by 16
Inflammation, Infiltration, and Evasion—Tumor Promotion in the Aging Breast
Cruz-Reyes, N., & Radisky, D. C. (2023) · Cancers · doi:10.3390/cancers15061836 · Cited by 16
Fully closed cell sorter for immune cell therapy manufacturing
Matsumoto, M., Tashiro, S., Ito, T., Takahashi, K., Hashimoto, G., Kajihara, J., Miyahara, Y., Shiku, H., & Katsumoto, Y. (2023) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2023.07.012 · Cited by 15
Precise surface functionalization of PLGA particles for human T cell modulation
Hadley, P., Chen, Y., Cline, L., Han, Z., Tang, Q., Huang, X., & Desai, T. A. (2023) · Nature Protocols · doi:10.1038/s41596-023-00887-8 · Cited by 15
Rahimi, A., Malakoutikhah, Z., Rahimmanesh, I., Ferns, G. A., Nedaeinia, R., Ishaghi, S. M. M., Dana, N., & Javanmard, S. H. (2023) · Cancer Cell International · doi:10.1186/s12935-023-03134-y · Cited by 15
Modeling immunity in microphysiological systems
Kwee, B. J., Li, X., Nguyen, X.-X., Campagna, C., Lam, J., & Sung, K. E. (2023) · Experimental Biology and Medicine · doi:10.1177/15353702231215897 · Cited by 15
Gammelgaard, O. L., Terp, M. G., Kirkin, A. F., Johansen, S., Traynor, S., Vever, H., Guldberg, P., Kodahl, A. R., Gjerstorff, M. F., & Ditzel, H. J. (2024) · Molecular Cancer · doi:10.1186/s12943-023-01914-8 · Cited by 15
CRISPRa engineered Elite macrophages enable adoptive cell therapy for rheumatoid arthritis
Huang, Y., Wang, Z., Zhong, C., Chen, H., Chen, X., Cao, C., Qiu, F., Xie, D., Li, J., Li, J., et al. (2024) · The Innovation Medicine · doi:10.59717/j.xinn-med.2024.100050 · Cited by 15
The Chemokine CXCL14 as a Potential Immunotherapeutic Agent for Cancer Therapy
Giacobbi, N. S., Mullapudi, S., Nabors, H., & Pyeon, D. (2024) · Viruses · doi:10.3390/v16020302 · Cited by 15
Immune landscape and response to oncolytic virus-based immunotherapy
Lin, C., Teng, W., Yang, T., Li, S., Xia, N., & Huang, C. (2024) · Frontiers of Medicine · doi:10.1007/s11684-023-1048-0 · Cited by 15
Sant, M., Vener, C., Lillini, R., Rossi, S., Bonfarnuzzo, S., Marcos-Gragera, R., Maynadié, M., Innos, K., Paapsi, K., Visser, O., et al. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00141-4 · Cited by 17
Immunotherapies for locally aggressive cancers
Adams, S. C., Nambiar, A., Bressler, E. M., Raut, C. P., Colson, Y. L., Wong, W. W., & Grinstaff, M. W. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115331 · Cited by 15
STING‐Activating Small Molecular Therapeutics for Cancer Immunotherapy
Huang, C., Tong, T., Ren, L., & Wang, H. (2024) · ChemBioChem · doi:10.1002/cbic.202400255 · Cited by 15
Yin, S., Li, C., Shen, X., Yu, G., Cui, L., Wu, Y., He, Y., Yu, S., Chen, J., Lu, S., et al. (2024) · Advanced Science · doi:10.1002/advs.202403438 · Cited by 15
Kushwaha, N., Panjwani, D., Patel, S., Ahlawat, P., Yadav, M. R., & Patel, A. (2024) · Journal of drug targeting · doi:10.1080/1061186x.2024.2417012 · Cited by 16
Fu, Z., Huang, Z., Xu, H., Liu, Q., Li, J., Song, K., Deng, Y., Tao, Y., Zhang, H., Wang, P., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci178558 · Cited by 18
Luan, D., DeWolf, S., Fei, T., Raj, S. S., Shah, G. L., Lareau, C. A., Alhomoud, M., Salles, G., Rivas‐Delgado, A., Rejeski, K., et al. (2024) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-24-0163 · Cited by 15
Wu, S., Xiang, R., Zhong, Y., Zhao, S., Zhang, Z., Kou, Z., Zhang, S., Zhao, Y., Zu, C., Gan, Z., et al. (2025) · npj Vaccines · doi:10.1038/s41541-024-01055-z · Cited by 19
Hernández-López, A., Olaya‐Vargas, A., Bustamante‐Ogando, J. C., & Meneses‐Acosta, A. (2025) · Pharmaceuticals · doi:10.3390/ph18020156 · Cited by 20
Potential target within the tumor microenvironment - MT1-MMP
Liu, J., Li, Y., Lian, X., Zhang, C., Feng, J., Tao, H., & Wang, Z. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1517519 · Cited by 17
Overcoming tumor heterogeneity by ex vivo arming of T cells using multiple bispecific antibodies
Park, J. A., & Cheung, N. V. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003771 · Cited by 15
Targeting SARS‐CoV ‐2 infection through CAR‐T ‐like bispecific T cell engagers incorporating ACE2
Dogan, M., Kozhaya, L., Placek, L., Karabacak, F., Yiğit, M., & Unutmaz, D. (2022) · Clinical & Translational Immunology · doi:10.1002/cti2.1421 · Cited by 18
Engineering self-propelled tumor-infiltrating CAR T cells using synthetic velocity receptorsPreprint
Johnston, A. C., Alicea, G. M., Lee, C., Patel, P. V., Hanna, E. A., Vaz, E., Forjaz, A., Wan, Z., Nair, P. R., Lim, Y., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.12.13.571595 · Cited by 18
Molecular Matchmakers: Bioconjugation Techniques Enhance Prodrug Potency for Immunotherapy
Chen, Y., Clay, N., Phan, N., Lothrop, E., Culkins, C., Robinson, B., Stubblefield, A., Ferguson, A., & Kimmel, B. R. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c00867 · Cited by 14
Ghaneialvar, H., Jahani, S., Hashemi, E., Khalilzad, M. A., Falahi, S., Rashidi, M. A., Majidpoor, J., & Najafi, S. (2024) · Human Immunology · doi:10.1016/j.humimm.2024.111209 · Cited by 14
Gene Therapy: Towards a New Era of Medicine
Bhagat, M., Kamal, R., Sharma, J., Kaur, K., Sharma, A. K., Singh, T. G., Bhatia, R., & Awasthi, A. (2024) · AAPS PharmSciTech · doi:10.1208/s12249-024-03010-6 · Cited by 16
New player in CAR-T manufacture field: comparison of umbilical cord to peripheral blood strategies
Rassek, K., Misiak, J., Ołdak, T., Rozwadowska, N., Basak, G. W., & Kolanowski, T. J. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1561174 · Cited by 14
Challenges and perspectives of CAR-T cell therapy in solid tumours: insights from gastric cancer
Zhou, J. (2025) · British Journal of Cancer · doi:10.1038/s41416-025-03100-7 · Cited by 14
González‐Martínez, B., Galán‐Gómez, V., Navarro‐Zapata, A., Mirones, I., Cobo, M., Pernas, A., Vallejo, S., Sánchez‐Zapardiel, E., León‐Triana, O., Echecopar, C., et al. (2025) · EBioMedicine · doi:10.1016/j.ebiom.2025.105872 · Cited by 18
Cancer Stem Cells Decide the Fate of Cancer Immunotherapy by Remodeling Tumor Microenvironment
Chakraborty, S., Basak, U., Mukherjee, S., Mukherjee, S., & Das, T. (2025) · Cancer Control · doi:10.1177/10732748251381441 · Cited by 16
Tumour priming by ultrasound mechanogenetics for CAR T therapy
Yoon, C. W., Song, C., Nguyen, D. N. M., Yu, X., Zhu, L., Ho, P., Huang, Z., Lu, G., Wang, Y., Wei, F., et al. (2025) · Nature Materials · doi:10.1038/s41563-025-02391-8 · Cited by 21
CRISPR-engineered microbiome: living therapeutics revolutionize blood cancer immunotherapy
Cheng, F., Samarkhazan, H. S., & Khazaei, Y. (2025) · npj Biofilms and Microbiomes · doi:10.1038/s41522-025-00882-9 · Cited by 15
Zurowski, D., PATEL, S. N., Hui, D. J., Ka, M. B., Hernandez, C., Love, A. C., Lin, B., Moore, A., & Chan, L. L. (2023) · SLAS DISCOVERY · doi:10.1016/j.slasd.2023.01.008 · Cited by 14
Wang, G., Su, H., Guo, Z., Li, H., Jiang, Z., Cao, Y., & Li, C. (2023) · Phytomedicine · doi:10.1016/j.phymed.2023.155029 · Cited by 14
Trends and Technology Development in Life Science
Dr. Sheeba, E. (2023) · doi:10.22192/ttdls.2023 · Cited by 14
Immunotherapy: breakthrough in Cancer Treatment
Gopalakrishnan, R., & Thamaraiselvi, B. (2023) · doi:10.22192/ttdls.2023.010 · Cited by 14
Genetically Modified Organisms (GMOs): Balancing Benefits and Ethical Considerations
Deepa, V. H., & Pushp, P. (2023) · doi:10.22192/ttdls.2023.011 · Cited by 14
The Landscape of Adoptive Cellular Therapies in Ovarian Cancer
Davis, L., Miller, R. E., & Wong, Y. N. S. (2023) · Cancers · doi:10.3390/cancers15194814 · Cited by 14
Targeting CDH17 with Chimeric Antigen Receptor-Redirected T Cells in Small Cell Lung Cancer
Tian, W., Zhao, J., & Wang, W. (2023) · Lung · doi:10.1007/s00408-023-00648-0 · Cited by 14
Progress and Pitfalls of Chimeric Antigen Receptor T Cell Immunotherapy against T Cell Malignancies
Angelos, M. G., Patel, R. P., Ruella, M., & Barta, S. K. (2023) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2023.10.013 · Cited by 16
Adoptive NK Cell Therapy - a Beacon of Hope in Multiple Myeloma Treatment
Vu, S. H., Pham, H. H., Pham, T. T. P., Le, T. T., Vo, M.-C., Jung, S., Lee, J., & Nguyen, X. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1275076 · Cited by 14
Pan, C., Jiang, X., Liu, C., Wei, J., Wang, Y., Yang, C., & Gan, Y. (2023) · Chemical Engineering Journal · doi:10.1016/j.cej.2023.148120 · Cited by 16
Novel immunotherapies for breast cancer: Focus on 2023 findings
Lan, H., Chen, M., Yao, S.-Y., Chen, J.-X., & Jin, K. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.111549 · Cited by 15
Clinical Potential of YY1-Hypoxia Axis for Vascular Normalization and to Improve Immunotherapy
Meo, C., & de Nigris, F. (2024) · Cancers · doi:10.3390/cancers16030491 · Cited by 14
Colina, A. S., Shah, V., Shah, R. K., Kozlik, T., Dash, R. K., Terhune, S. S., & Zamora, A. E. (2024) · Frontiers in Molecular Medicine · doi:10.3389/fmmed.2024.1310002 · Cited by 12
Ip, A., Mutebi, A., Wang, T., Jun, M. P., Kalsekar, A., Navarro, F. R., Wang, A., Kamalakar, R., Sacchi, M., & Elliott, B. (2024) · Advances in Therapy · doi:10.1007/s12325-023-02775-9 · Cited by 14
Gao, F., You, X., Yang, L., Zou, X., & Sui, B. (2024) · International Reviews of Immunology · doi:10.1080/08830185.2024.2333275 · Cited by 14
Hadiloo, K., Taremi, S., Safa, S. H., Amidifar, S., & Esmaeilzadeh, A. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107158 · Cited by 14
Applications of self-assembled peptide hydrogels in anti-tumor therapy
Hua, Y., & Shen, Y. (2024) · Nanoscale Advances · doi:10.1039/d4na00172a · Cited by 15
CAR-T Cell Therapy in Pancreatic and Biliary Tract Cancers: An Updated Review of Clinical Trials
Drougkas, K., Karampinos, K. I., Karavolias, I., Gomatou, G., Koumprentziotis, I., Ploumaki, I., Triantafyllou, E., & Kotteas, E. A. (2024) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-024-01054-2 · Cited by 15
Ye, Z., Cheng, P., Huang, Q., Hu, J., Huang, L., & Hu, G. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1388176 · Cited by 15
The biological roles of CD47 in ovarian cancer progression
Xing, L., Wang, Z., Feng, Y. M., Luo, H., Dai, G.-J., Sang, L., Zhang, C., & Qian, J. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03708-3 · Cited by 14
The art of designed coiled-coils for the regulation of mammalian cells
Plaper, T., Rihtar, E., Ramuta, T. Ž., Forstnerič, V., Jazbec, V., Ivanovski, F., Benčina, M., & Jerala, R. (2024) · Cell chemical biology · doi:10.1016/j.chembiol.2024.06.001 · Cited by 15
Atypical artificial cells: Novel biomimetic materials for combating cancer
Ren, Z., Wan, Q., Zhu, Y., Li, L., Wang, K., Zhao, F., Jiao, K., Tang, M., Tay, F. R., Wan, M., et al. (2024) · Interdisciplinary materials · doi:10.1002/idm2.12199 · Cited by 15
Generation of non-genetically modified, CAR-like, NK cells
Coënon, L., Rigal, É., Courot, H., Multrier, C., Zemiti, S., Lambour, J., Pugnière, M., de Toledo, M., Bossis, G., Cartron, G., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009070 · Cited by 14
Shifana, A. S., Adnan, M., Gupta, A., Ajazuddin, M., & Jain, P. (2024) · Current Cancer Drug Targets · doi:10.2174/0115680096312603240709112520 · Cited by 16
Mai, Q., He, B., Deng, S., Zeng, Q., Xu, Y., Wang, C., Pang, Y., Zhang, S., Li, J., Zeng, J., et al. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00553-z · Cited by 14
Design of nanosystems for melanoma treatment
Farasatkia, A., Maeso, L., Gharibi, H., Dolatshahi‐Pirouz, A., Stojanović, G. M., Antezana, P. E., Jeong, J., Desimone, M. F., Orive, G., & Kharaziha, M. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.124701 · Cited by 14
Ploch, W., Sadowski, K. A., Olejarz, W., & Basak, G. W. (2024) · Cancers · doi:10.3390/cancers16193339 · Cited by 13
Enhancing CAR-T cell therapy against solid tumor by drug-free triboelectric immunotherapy
Li, H., Wang, Z., Hu, Y., He, G., Huang, L., Liu, Y., Wang, Z. L., & Jiang, P. (2024) · Biomaterials · doi:10.1016/j.biomaterials.2024.122871 · Cited by 14
Significant Advancements and Evolutions in Chimeric Antigen Receptor Design
Gaimari, A., Lucia, A. D., Nicolini, F., Mazzotti, L., Maltoni, R., Rughi, G., Zurlo, M., Marchesini, M., Juan, M., Parras, D., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252212201 · Cited by 16
Powering immunity: mitochondrial dynamics in natural killer cells
Verhezen, T., Wouters, A., Smits, E., & Waele, J. D. (2025) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2025.04.004 · Cited by 13
Schindler-Wnek, K., Stahringer, A., Heimer, N., Koehl, U., Fricke, S., & Schmiedel, D. (2025) · Oncoimmunology · doi:10.1080/2162402x.2025.2546443 · Cited by 12
Wang, D., Gu, W., Chen, W., Zhou, J., Yu, L., Kim, B. K., Zhang, X., & Kim, J. S. (2022) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2022.214788 · Cited by 14
Selection and Identification of an ssDNA Aptamer for Fibroblast Activation Protein
Zhang, X., Yang, G. H., Zhao, Y., Dai, X., Liu, W., Qu, F., & Huang, Y. (2023) · Molecules · doi:10.3390/molecules28041682 · Cited by 13
Sonnemann, H. M., Pazdrak, B., Antunes, D. A., Roszik, J., & Lizee, G. A. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.188892 · Cited by 15
Metadata
- Authors
- Sterner, R. C., & Sterner, R. M.
- Affiliations
- Mayo Clinic (US)
- Corresponding author
- Sterner, Rosalie M.
- Venue
- Blood Cancer Journal
- Published
- 2021-04-06
- Volume
- 11
- Issue
- 4
- Pages
- 69-69
- ISSN
- 2044-5385 (ISSN-L)
- PMC
- PMC8024391
- OpenAlex
- W3148729173
- Cited by
- 2,926
- References
- 110
- Citations by year
- 2026: 530 · 2025: 806 · 2024: 726 · 2023: 532 · 2022: 287 · 2021: 42
- FWCI
- 48.36
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Blood Cancer Journal (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- University of Wisconsin-Madison (T32-GM008692)
- Regenerative Medicine Minnesota (RMM 012819 EPC 003)
- National Institute of General Medical Sciences (T32GM008692)
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- CAR T-cell therapy, chimeric antigen receptor, solid tumors, hematologic malignancies, CAR-T cell engineering, tumor microenvironment, antigen escape, CAR-T toxicity, tumor infiltration
- MeSH terms
- Receptors, Chimeric Antigen, Animals, Humans, Neoplasms, T-Lymphocytes, Immunotherapy, Adoptive, Hematologic Neoplasms, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
